Intuitive Surgical drops 12% as 2026 procedure outlook disappoints

Intuitive Surgical's conservative 2026 procedure growth outlook overshadowed a strong second-quarter earnings beat, sending shares down 12% in pre-market trading as investors weighed whether the robotic surgery pioneer's expansion is losing momentum.

"The market is focused on the deceleration signal rather than the absolute growth rate," TD Cowen analysts said in a note, maintaining a Buy rating while lowering their price target to $520 from $585. The brokerage cited competitive pressures, remanufactured surgical instruments, and international market challenges as factors weighing on sentiment.

The company reported adjusted earnings of $2.80 per share for the quarter, beating the $2.51 consensus, while revenue rose 19% year over year to $2.89 billion, above estimates of $2.82 billion. Worldwide da Vinci procedures increased about 15% and Ion procedures surged 36%, with 468 systems placed during the quarter, including 246 of the latest da Vinci 5 platform. The installed base grew 12% to 11,710 da Vinci systems, while Ion's installed base expanded 21% to 1,096 units.

The 2026 forecast of 13.5% to 15.5% procedure growth, with management expecting results near the 14.5% midpoint, represents a slowdown from the 16% growth recorded in the second quarter. The guidance also comes after hospital operator HCA Healthcare warned of softer surgical demand and rising uninsured patients following the expiration of pandemic-era Affordable Care Act subsidies, raising questions about whether broader healthcare policy shifts could pressure procedure volumes across the sector.

Da Vinci 5 Adoption Accelerates, But Competition Intensifies

The company placed 246 da Vinci 5 systems in the quarter, signaling strong uptake of its newest platform. Revenue from instruments and accessories, Intuitive's largest and most recurring business, climbed 18% to $1.73 billion, while systems revenue rose to $685 million from $575 million a year ago. The company also benefited from a one-time tariff-related refund worth $28 million after tax, equivalent to $0.08 per share.

Management guided for 2026 adjusted gross margins of 68% to 69% of revenue, an improvement from its earlier forecast of 67.5% to 68.5%, though the outlook includes an estimated one percentage point impact from tariffs. Adjusted operating expense growth is expected to be 11% to 13%.

The US robotic surgery market is entering its first significant competitive phase in more than two decades after Intuitive largely dominated the segment. Stifel maintained a Buy rating and $670 price target following a survey of 100 robotic surgeons, who continued to view Intuitive's technology leadership favorably despite the emergence of new competitors. Recently announced upgrades to the da Vinci 5 platform further strengthen the company's competitive position, according to Stifel.

Valuation Compression Opens Debate on Entry Point

Intuitive Surgical shares have declined about 29% this year, reflecting concerns over slowing growth, increasing competition, and a premium valuation. The forward price-to-earnings multiple has compressed to around 36 times, well below the five-year average of more than 58 times, according to The Motley Fool's James Halley.

"This compression offers a much more attractive entry point into a company where more than 80% of revenue is highly durable and recurring, from instruments, accessories, and services," Halley said.

Wall Street remains broadly positive despite the recent weakness. Among 35 analysts covering the stock, 24 recommend buying, 10 rate it a Hold, and only one recommends selling. The consensus price target has moderated to $521.37 from $556.89, with forecasts ranging from $366 to $750 per share, implying roughly 30% upside from Wednesday's closing price.

The central question for investors is whether the 2026 guidance reflects genuine demand headwinds from policy changes and competition, or a conservative buffer that Intuitive will exceed as it has historically. With more than 80% of revenue tied to recurring instruments and services, the installed base provides a durable revenue floor — but the pace of new procedure growth will determine whether the stock's valuation multiple can expand again.

This article is for informational purposes only and does not constitute investment advice.